Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Assets (2016 - 2025)

Traws Pharma (TRAW) has disclosed Current Assets for 14 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For Q4 2025, Current Assets fell 68.02% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, down 68.02%, while the annual FY2025 figure was $8.0 million, 68.02% down from the prior year.
  • Current Assets hit $8.0 million in Q4 2025 for Traws Pharma, down from $9.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $59.9 million in Q3 2021 and bottomed at $8.0 million in Q4 2025.
  • Average Current Assets over 5 years is $31.4 million, with a median of $28.7 million recorded in 2023.
  • Year-over-year, Current Assets surged 180.18% in 2021 and then crashed 68.02% in 2025.
  • Traws Pharma's Current Assets stood at $55.4 million in 2021, then decreased by 29.01% to $39.3 million in 2022, then tumbled by 42.41% to $22.7 million in 2023, then grew by 10.11% to $25.0 million in 2024, then plummeted by 68.02% to $8.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $8.0 million, $9.6 million, and $15.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.